Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Aja Otten"'
Autor:
Linda Dirven, Martin J.B. Taphoorn, Martin J. van den Bent, Nelly van der Meer, Maaike J. Vos, Jaap C. Reijneveld, Jacoline E C Bromberg, Filip de Vos, Marion Smits, Bronno van der Holt, Monique Hanse, Andrew Bottomley, Aja Otten, Walter Taal, Laurens V. Beerepoot, Annemiek M E Walenkamp
Publikováno v:
European Journal of Cancer, 51(10), 1321. Elsevier Limited
European journal of cancer (Oxford, England, 51(10), 1321-1330. Elsevier Limited
European Journal of Cancer, 51(10), 1321-1330. Elsevier Ltd.
European Journal of Cancer, 51(10), 1321-1330. Pergamon
European Journal of Cancer, 51(10), 1321-1330. ELSEVIER SCI LTD
Dirven, L, van den Bent, M J, Bottomley, A, van der Meer, N, van der Holt, B, Vos, M J, Walenkamp, A M E, Beerepoot, L V, Hanse, M C J, Reijneveld, J C, Otten, A, de Vos, F Y F L, Smits, M, Bromberg, J E C, Taal, W & Taphoorn, M J B 2015, ' The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial ', European Journal of Cancer, vol. 51, no. 10, pp. 1321-1330 . https://doi.org/10.1016/j.ejca.2015.03.025
European journal of cancer (Oxford, England, 51(10), 1321-1330. Elsevier Limited
European Journal of Cancer, 51(10), 1321-1330. Elsevier Ltd.
European Journal of Cancer, 51(10), 1321-1330. Pergamon
European Journal of Cancer, 51(10), 1321-1330. ELSEVIER SCI LTD
Dirven, L, van den Bent, M J, Bottomley, A, van der Meer, N, van der Holt, B, Vos, M J, Walenkamp, A M E, Beerepoot, L V, Hanse, M C J, Reijneveld, J C, Otten, A, de Vos, F Y F L, Smits, M, Bromberg, J E C, Taal, W & Taphoorn, M J B 2015, ' The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial ', European Journal of Cancer, vol. 51, no. 10, pp. 1321-1330 . https://doi.org/10.1016/j.ejca.2015.03.025
Background: The BELOB study, a randomised controlled phase 2 trial comparing lomustine, bevacizumab and combined lomustine and bevacizumab in patients with recurrent glioblastoma, showed that the 9-month overall survival rate was most promising in th